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Abstract 
Background and objectives: Joubert syndrome (JS) is a genetically heterogeneous ciliopathy 
associated with more than 30 genes. The characteristics of kidney disease and genotype-
phenotype correlations have not been evaluated in a large cohort at a single center.  
Design, setting, participants, and measurements: We evaluated 97 individuals with JS at the NIH 
Clinical Center including abdominal ultrasonography, blood and urine chemistries, and DNA 
sequencing.  
Results:  Patients were ages 0.6 to 36 years (mean 9.0 + 7.6); 41 were female. Mutations were 
identified in 19 genes in 92 patients; two-thirds of the mutations resided in 6 genes: TMEM67, 
C5orf42, CC2D2A, CEP290, AHI1, and KIAA0586. Kidney disease was detected in 30%, most 
commonly in association with the following genes: CEP290 (6/6), TMEM67 (11/22), and AHI1 
(3/6). No kidney disease was identified in patients with mutations in C5orf42 (0/15) or 
KIAA0586 (0/6). Prenatal ultrasonography of kidneys was normal in 72% of patients with kidney 
disease. Specific types of kidney disease included nephronophthisis (31%), an overlap phenotype 
of autosomal recessive polycystic kidney disease (ARPKD)/nephronophthisis (35%), unilateral 
multicystic dysplastic kidney (10%), and indeterminate type cystic kidney disease (24%). Early-
onset hypertension occurred in 24% of patients with kidney disease.  Age at end-stage kidney 
disease (n=13) ranged from 6 to 24 years (mean, 11.3 + 4.8).  
Conclusions: Kidney disease occurs in up to one-third of JS patients, most commonly in those 
with mutations in CEP290, TMEM67 and AHI1. Patients with mutations in C5orf42 or 
KIAA0586 are less likely to develop kidney disease. Prenatal ultrasonography is a poor predictor 
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of kidney involvement in JS. Unilateral multicystic dysplastic kidney and ARPKD-like enlarged 
kidneys with early-onset hypertension can be part of the JS kidney phenotype.  
 
Introduction 
Fibrocystic kidney disease is a common feature in many ciliopathies including Meckel, Bardet-
Biedl and Joubert syndromes (JS)(1, 2).  First described in 1969(3), JS (OMIM 213300) is 
defined based on a characteristic set of cerebellum and midbrain abnormalities that collectively 
result in the diagnostic “molar tooth sign” on axial brain images(4) (Figure 1). The incidence of 
JS is estimated to range between 1:80,000 and 1:100,000(5). Core clinical features of JS 
observed shortly after birth include hypotonia and episodic tachypnea and/or apnea, followed 
later by developmental delay, ocular motor apraxia, truncal ataxia and speech apraxia(5, 6). Most 
patients have extra-neurological involvement that can include polydactyly, chorioretinal 
colobomas, retinal degeneration, congenital hepatic fibrosis, and/or fibrocystic kidney disease(5, 
7). This clinical heterogeneity led to the use of the term Joubert syndrome and related disorders 
which includes Senior-Løken (nephronophthisis and retinal degeneration) and COACH 
(colobomas, "oligophrenia" for cognitive impairment, ataxia, cerebellar vermis hypoplasia, 
and hepatic fibrosis) syndromes(8). For simplicity, the term JS refers to all patients with the 
“molar tooth sign” including patients with or without non-neurological disease(6). In this article, 
we use JS to include Senior-Løken and COACH syndromes.  
Like other syndromic ciliopathies, JS is characterized by extreme genetic heterogeneity, with 
more than 30 causative genes(5). The frequency of kidney disease in individual gene-specific 
subtypes of JS remains unknown; estimates range from 25% to 27%(9, 10). Most publications on 
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kidney involvement in the disease have been limited to small case series or retrospective 
multicenter reports based on questionnaires and medical records review(7, 9, 11-13). In1992, 
Saraiva and Baraitser(9) claimed kidney disease and retinal disease in JS were closely linked and 
only patients with retinal dystrophy were at risk for fibrocystic kidney disease. However,  many 
individuals with JS and kidney disease but no retinal degeneration have since been reported(5, 
7).  While the nephronophthisis in Senior-Løken syndrome(14) and cystic dysplastic kidneys in 
Arima syndrome(7) are relatively well described, the kidney disease in other JS patients is often 
reported in non-specific terms, noting only absence or presence of  “kidney cysts” and neglecting 
data on features such as blood pressure, kidney function, and delineation of the exact type of the 
fibrocytic kidney disease. Although many of the over 30 causative JS genes, including CEP290, 
NPHP1, AHI1, OFD1, RPGRIP1L, CC2D2A, TMEM67, TMEM216, TMEM138, and TMEM237, 
have been associated with kidney disease, correlations between genotype and kidney disease 
remain largely unknown(5, 15, 16).  
Here we describe the characteristics of kidney disease in 97 JS patients prospectively evaluated 
at a single center. We detail kidney ultrasonography (US), magnetic resonance imaging (MRI) of 
the kidneys, and kidney function tests in the context of the molecular genetic diagnosis, as well 
as other organ involvement including liver disease and ophthalmological features.   
Materials and Methods 
Patients 
All patients were prospectively evaluated at the National Institutes of Health (NIH) Clinical 
Center, between 2003 and 2014, under the intramural NIH research protocol, “Clinical and 
Molecular Investigations Into Ciliopathies”(www.clinicaltrials.gov, trial NCT00068224), 
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approved by the NHGRI Institutional Review Board. The study was advertised by the Joubert 
Syndrome & Related Disorders Foundation. Patients and/or their parents gave written, informed 
consent.  
 
Enrollment required a clinical diagnosis of JS based on the pathognomonic “molar tooth sign” on 
brain MRI. For recruitment, the study was advertised to individuals with JS and their families by 
The Joubert Syndrome and Related Disorders Foundation as a natural history study aiming to 
describe the individual organ system involvement in JS including kidney disease. To minimize 
ascertainment bias, all travel, lodging, and other participation costs, as well as clinical and 
laboratory evaluations, were sponsored by the NIH. A total of 120 patients from 105 families 
who reported to be diagnosed with JS based on brain MRI applied. Brief phone interviews 
answering parents’ questions on risks and benefits of the study evaluations were performed by 
the senior investigator (MGA) on all 120 individuals with JS  from 105 families; no patients 
were excluded at this stage. Fifteen patients could not travel to the NIH Clinical Center in 
Bethesda, Maryland, in some cases due to the severity of neurological symptoms. The remaining 
105 JS patients from 90 families underwent week-long clinical evaluations at the NIH Clinical 
Center. Eight patients from 6 families (including 3 patients with the classical kidney and retina 
findings of Senior-Løken syndrome) were excluded because they did not have the “molar tooth 
sign” on our review of their brain MRI images(17),.The remaining 97 patients were included in 
this study.  
 
All patients were evaluated by the last author (MGA); evaluations included past medical history, 
family history, physical examination, review of past medical records, review of brain magnetic 
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resonance images, high resolution complete abdominal US (all patients), abdominal MRI (13 
patients who were able to cooperate for the study without sedation), complete ophthalmologic 
examination, and comprehensive blood and urine chemistries. Glomerular filtration rate (GFR) 
was calculated using pediatric(18) and adult(19) formulas. Blood samples for DNA were 
collected from all patients and parents, when available.  
 
Kidney disease was defined based on GFR and/or abnormal findings on kidney US including 
increased echogenicity, increased or decreased kidney size, and/or cystic changes. Liver disease 
was defined by elevated liver enzymes and/or increased echogenicity of the liver and/or 
splenomegaly on abdominal US. Retinal degeneration was based on typical findings on retinal 
examination after dilation of pupils. All available brain MR images were qualitatively evaluated 
by a team of five physicians, including two pediatric neuroradiologists, one adult 
neuroradiologist, one pediatric neurologist and one pediatric clinical geneticist (MGA), as a 
group to achieve consensus(17).  
 
Molecular Inversion Probes (MIP), Whole exome and Sanger Sequencing 
The coding exons of 27 genes associated with JS were sequenced by combining a MIP capture 
method and next-generation sequencing as previously described(20). In addition, exome 
sequencing was performed using the HiSeq2000 (Illumina, San Diego, CA)(21) and analyzed as 
previously described(20). For further details, please refer to supplementary methods.  
 
Statistical Methods 
Ranges, averages and standard deviations were calculated.  
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Serum cystatin C was not available in 4 children (Table 1S, patients 26, 31, 82, and 83), due to 
problems in handling of blood specimens. For these patients, GFR was calculated using an 
alternative formula based on height and serum creatinine(22). Abdominal MRI was performed in 
13 of 97 patients who were able to tolerate this study without anesthesia. Therefore, to evaluate 
kidney size ultrasonography based kidney length which was available on all patients was used.   
Results 
Patient Cohort 
Table 1S shows the molecular genetic findings in 97 patients, as well as their major clinical 
features including kidney disease, retinal degeneration, coloboma, liver disease and polydactyly. 
There were 41 females and 56 males. Ages ranged from 0.6 to 36 years (mean 9.0 + 7.6 years) 
(Table1S). Nine families had 2 siblings (Families 6, 7, 8, 18, 24, 29, 36, 65, and 78) and 2 
families had 3 siblings with JS  (Families 16 and 66) evaluated at the NIH. In addition, 4 other 
families represented in this study by a single patient, (Table 1, families 5, 14, 34 and 44) and 
family 66 had another affected deceased child.  
 
The molecular genetic cause was identified in 19 different JS genes in all but 5 families; detailed 
molecular genetic findings of this cohort were reported seperately (20) (Table 1S). Mutations for 
two-thirds of the families resided in 6 genes: TMEM67 (20%), C5orf42 (14%), CC2D2A (11%), 
CEP290 (8%), AHI1 (7%), and KIAA0586 (7%). Each of the remaining 13 genes accounted for a 
small proportion of the families, ranging from 1-6%: MKS1 (6%), INPP5E (4%), NPHP1 (1%), 
TMEM216 (2%), OFD1 (2%), CSPP1 (2%), TMEM231 (1%), KIF7 (1%), B9D1 (1%), 
RPGRIP1L (1%), TMEM237 (1%), KIAA0753 (1%), and CELSR2 (1%). 
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Retinal degeneration was detected in 20%, coloboma in 30%, polydactyly in 13%, and liver 
involvement in 43% (Table 1S).  
 
Kidney Disease 
Kidney involvement was identified in 29 patients; in the remaining 68 patients, kidney US and 
GFR were normal and there was no hypertension or chronic anemia. (Tables 1 and 2). Four 
patients with kidney disease (Table 2, patients 9, 16, 53 and 73) underwent kidney 
transplantation prior to their NIH evaluation. Of the remaining 25 patients with kidney 
involvement, 24 had abnormalities on kidney US; 13 of these 24 had decreased GFR (Table 2). 
One patient had decreased GFR with normal kidney US.  
Kidney Transplantation 
At the time this paper was written,  13 of the 29 JS patients with kidney involvement had reached 
end stage kidney disease (ESRD) at ages 6-24 years (mean 11.3 + 4.8 years); 7 patients have 
undergone transplantation after their NIH evaluation (Table 2, patients  3, 5, 8, 13, 50, 54, and 
97) and 2 other patients (Table 2, patients 52 and 80) reached ESRD at age 12 years, but have 
not yet been transplanted.  
Kidney-related Findings on Prenatal Ultrasonography 
Prenatal kidney US was abnormal in only 8 (28%) of the 29 patients with kidney disease (Table 
2, patients 5, 8, 13, 50, 53, 56, 72 and 89). In 2 other affected individuals (Table 1S, patients 17 
and 42) prenatal US was normal, but their mothers had other affected pregnancies with enlarged 
diffusely cystic kidneys resulting in fetal demise. In 4 patients (Table 2, patients 5, 8, 13, and 
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89), enlarged, hyperechogenic kidneys with or without discrete cysts and/or oligohydramnios 
were seen at gestational age 19-20 weeks. The mother of patient 5 had another pregnancy with 
similar US findings at 19 weeks. In patient 53, who required kidney transplantation at age 9 
years, prenatal US at 19 weeks showed hyperechogenic kidneys that returned to normal on repeat 
US in the third trimester. Patient 72 had polyhydramnios during the 8th month of pregnancy. In 
patient 3, prenatal US was normal but oligohydramnios was diagnosed at delivery and the 
infant’s kidneys were palpable at birth. In 2 patients (50 and 56), the kidney abnormality was 
unilateral; US at the 20
th
 week of gestation in each infant showed left multi-cystic dysplastic 
kidney (MCDK) and the right kidney was normal.  
Kidney Imaging Findings at the NIH Clinical Center  
The most common abnormality on kidney US was increased echogenicity involving both cortex 
and medulla, resulting in loss of corticomedullary differentiation with or without discrete cysts 
(11 of 24 patients with abnormal US). In 5 of these 11 patients (Table 2, patients 3, 5, 8, 13, and 
89), the kidneys were perinatally enlarged; 1 of these patients still had enlarged kidneys at the 
time of NIH evaluation at age 8 years (Table 2, patient13). In the remaining 4 kidney sized 
normalized or became smaller over time (Figure 2A and B). Patient 60 with left multicystic 
dysplastic kidney, had an enlarged right kidney likely due to compensatory hypertrophy; in the 
remaining 24 patients with kidney disease kidney size was either normal or small (Table 2). In 4 
patients (Table 2, patients 40, 52, 54, and 79) cysts and/or hyperechogenicity were confined to 
medulla (Figure 2D). Asymmetric kidney disease was identified in 4 patients (Table 2, patients 
50, 56, 59 and 60), including 3 with left MCDK (Figure 2E and F). Patient 56’s nuclear scan at 
age 12 months failed to demonstrate any kidney function of the left kidney (Figure 2F) and US at 
19 months showed a normal right kidney, and a small left-sided hypoechoic mass that may have 
11 
 
represented an atrophic kidney; his kidney function and voiding cystourethrogram were normal. 
Patient 59’s yearly US examinations between ages 1 to 7 were completely normal. At age 7 
years, the only abnormal finding was a small cortical cyst at upper pole of left kidney; annual US 
imaging between ages 7 and 13 remained otherwise normal. At age 17 years, both kidneys were 
hyperechogenic; left kidney (length at -0.7 SD) had several large cysts in upper pole while right 
kidney was relatively larger (length at +1.9 SD) with a few small cortical cysts.  
 
Kidney Histopathology Findings 
Histopathology of 3 kidney explants (Table 2, patients 8, 9, and 16) showed severe tubular 
atrophy, interstitial fibrosis, chronic inflammation, variable degrees of glomerulosclerosis, 
nephrocalcinosis as well as cysts, mostly accumulated at the CM junction but also scattered 
throughout the cortex and medulla. 
Early-onset Hypertension  
Of the 29 patients with kidney disease, 7 had early-onset hypertension diagnosed shortly after 
birth or within the first years of life, before any measurable decrease in GFR (Table 2). Patient 9 
was screened at age 3 years after his sister’s diagnosis of “polycystic kidneys”; he had 
cardiomyopathy secondary to undiagnosed early-onset severe hypertension which resolved after 
treatment.    
Discussion 
The frequency of kidney disease in our JS cohort was 30%, slightly higher than published 
estimates of 25 to 27 % (9, 10), perhaps a reflection of our comprehensive evaluations performed 
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specifically to detect kidney disease. The percentage of individuals with kidney disease may also 
increase with age; our cohort’s mean age was 9 years.  
Nephronophthisis was present in 31 % of our JS patients with kidney disease, and it resembled 
the kidney disease of  non-syndromic nephronophthisis(23, 24). Clinically, kidney size was 
normal or small, with increased echogenicity and a few cysts at the corticomedullary junction. Of 
the 9 JS patients with nephronophthisis, 2 had Senior-Løken syndrome with retinal degeneration 
due to mutations in CEP290, andINPP5E; the 7 nephronophthisis patients with no retinal disease 
had mutations in CC2D2A, TMEM67 and NPHP1.  
A hybrid ARPKD-nephronophthisis pattern of kidney disease was present in 35% of JS patients 
with kidney disease. One characteristic feature of ARPKD(25) but not nephronophthisis(24), 
present in 7 patients, was early-onset severe hypertension (before any decrease in GFR). Another 
feature of ARPKD, enlarged kidneys, was seen in 5 patients, making the early differentiation of 
JS and ARPKD challenging. In fact, 3 patients (8, 9 and 13) were originally diagnosed as having 
ARPKD and carried this diagnosis until their NIH evaluation under our ARPKD study at ages 6, 
9 and 8 years, (respectively); at that time, their mild oculomotor apraxia and developmental 
delays made us suspect JS. An additional patient, (patient 3) was misdiagnosed as having 
ARPKD in addition to his known diagnosis of JS, which was the cause of his polycystic kidneys. 
Before making a prenatal diagnosis of ARPKD, cerebellar abnormalities and polydactyly should 
be excluded because renal disease in JS is indistinguishable from ARPKD. Only 13% of JS 
patients have polydactyly (Table 1), so a careful evaluation for brain anomalies is essential for 
prenatal differentiation of JS from ARPKD. In addition, if a child diagnosed as having ARPKD 
manifests developmental delay and/or ocular motor apraxia, a brain MRI should be performed 
because patients with JS with mild cerebellar involvement may be misdiagnosed as ARPKD.  
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The combination of coloboma, kidney disease and polydactyly strongly suggests a ciliopathy, 
specifically JS. Molecular studies can also be helpful, since 7 of the 10 patients in the ARPKD-
nephronophthisis group had mutations in TMEM67 and enlarged, ARPKD-like kidneys; indeed, 
mutations in TMEM67 also cause Meckel syndrome, another ciliopathy with cystic kidney 
disease(1).  
Our most surprising finding was unilateral MCKD in 3 JS patients (50, 56 and 60), two of whom 
had a completely normal contralateral kidney and normal GFR at ages 3 (patient 56) and 20 
years (patient 60) (Figure 2E and F, Table 2). Both of these patients had mutations in AHI1. 
While unilateral MCDK occurs as part of many syndromes, asymmetric kidney disease is 
unexpected in ciliopathies(1, 23). We are aware of MCDK reported in JS in the medical 
literature: one Iranian patient with JS and right-sided MCDK(26), and one with either unilateral 
kidney agenesis(7) or unilateral MCDK misdiagnosed as kidney agenesis due to resolution of the 
atrophic kidney(27). Of note, patient 60 in our cohort was part of a previously reported series 
(family K8062)(28). Recently, mutations in HNF1β and TBX18 have been identified in rare 
families with MCDK(29, 30)
,
(31). Our patients, however, had mutations in CEP290 and AHI1 as 
single gene causes of syndromic MCDK associated with JS.  
Modifier genes may influence the occurrence of kidney disease in JS (32). All 11sibling sets 
evaluated at NIH were concordant for kidney disease. However,  in two families, there was 
history of a deceased sibling who was discordant for presence of kidney disease (Table 1S and 
Table 3, families 34, and 66). In family 34 (Table 1S)patient 42 had no significant kidney disease 
at age 3.2 years, despite having an affected brother who passed away perinatally due to cystic 
kidneys. Similarly, in family 66, a 4th child passed away at birth with polycystic kidneys(33), 
while 3 other affected siblings (Table 1S, patients 76, 77 and 78) had normal kidney imaging and 
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function at  ages 15 months and 4 years 9 months (twins). It is possible that these patients may 
develop kidney disease as they get older.  
Prenatal US was abnormal in 28% of JS patients with kidney disease, representing a surprisingly 
low prenatal detection rate of kidney disease in JS. In another multisystem ciliopathy Bardet-
Biedl syndrome(34), Forsythe et al. reported a prenatal detection rate of 64% for kidney disease. 
This discrepancy in prenatal detection rates of kidney disease of patients with JS and Bardet-
Biedl syndromes may be due to the variation in the expertise of the prenatal ultrasonography 
specialists as well as differences in the nature of kidney disease among different ciliopathies.  
We can derive several important conclusions from this study. First, kidney disease affects up to 
one-third of JS patients, and is more common in those with pathogenic variants in CEP290, 
TMEM67 and AHI1 genes; it was not observed in patients with mutations in C5orf42 or 
KIAA0586. Second, the severity and progression of kidney disease appeared comparable across 
JS genotypes, with most patients requiring kidney transplantation in childhood-young adulthood. 
Third, prenatal US does not predict kidney disease well in JS; it was abnormal in only 28% of JS 
patients with kidney disease. Moreover, the prenatal kidney US findings in JS are 
indistinguishable from ARPKD, so fetuses with hyperechogenic kidneys should have careful 
imaging for other abnormalities, especially brain anomalies; in addition, polydactyly, if present 
can be a helpful sign of JS, although its absence does not exclude the condition. Fourth, early-
onset hypertension, before kidney function is decreased, occurred in 24% of JS patients with 
kidney disease, particularly those with enlarged, ARPKD-like, diffusely hyperechogenic 
kidneys. Fifth, in families with multiple children with JS, siblings are largely concordant for 
kidney disease, although exceptions exist. Based on these conclusions, we make several 
recommendations for surveillance. All patients with JS should have blood pressure measurement, 
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complete abdominal US, liver and kidney function tests, and complete blood counts at the time 
of diagnosis and annually thereafter. JS patients with unilateral MCDK should be radiologically 
assessed for other congenital anomalies of the kidney and urinary tract such as vesicoureteral 
reflux or contralateral ureteropelvic junction obstruction(27, 35) (36).   
Limitations 
Although this study represents the largest number of subjects with JS evaluated at a single center, 
the size of the cohort is still relatively small. Gene-phenotype correlations were not possible 
except for the most common genetic causes. Our cohort is likely enriched for JS patients with 
kidney and liver disease, because the comprehensive evaluations performed at the NIH Clinical 
Center may have attracted patients with these manifestations. However, our study also offered 
other investigations including neurocognitive testing, DNA sequencing, sleep studies, and 
echocardiograms, which may have minimized this bias. JS patients with severe disease such as 
those who required mechanical ventilation may be underrepresented, as they could not travel to 
Bethesda, MD. In addition, the overall frequency of kidney disease as well as other extra-
neurological manifestations may have been underestimated by this cross-sectional study because 
these manifestations may develop as the patient gets older.  
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Figure Legends 
Figure 1. Diagnostic brain imaging findings in Joubert Syndrome. A. Axial brain MRI 
obtained at the pontomesencephalic junction showing the molar tooth sign (“MTS”; circle) and 
hypoplastic cerebellar vermis (arrows) compared to normal (C). B. Mid-sagittal brain MRI 
demonstrating hypoplasia and dysplasia of the cerebellar vermis (circle) and enlarged fourth 
ventricle (asterisk) with rostral displacement of the fastigium compared to normal (D). 
 
Figure 2. Imaging findings in JS patients with kidney disease.  
A. Ultrasonographic image of patient 9 at age 4 years showing enlarged and hyperechogenic left 
kidney (outlined by the dots) with loss of corticomedullary differentiation. B. Patient 9’s kidney 
length (bold red line, average of right and left) plotted against age in comparison to normal mean 
(bold gray line) and +2 standard deviation (gray line). C. High resolution ultrasonographic image 
of patient 88’s left kidney displaying cysts in cortex. D. Ultrasonography image of patient 40’s 
left kidney showing medullary hyperechogenicity. E. T2-weighted coronal magnetic resonance 
image of patient 60 showing a left multicystic dysplastic kidney and normal right kidney. F. Tc-
99m nuclear scan (coronal image) of patient 56 at age 12 months showing no function of his left 
MCDK. This patient’s prenatal ultrasonography at 19 weeks of gestation showed a left MCDK 
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and a normal right kidney. On ultrasonography at age 3, his left kidney could not be visualized 
but his right kidney was normal. 
References 
1. Gunay-Aygun M: Liver and kidney disease in ciliopathies. American journal of medical genetics Part C, 
Seminars in medical genetics, 151C: 296-306, 2009 
2. Gunay-Aygun M, Parisi MA, Doherty D, Tuchman M, Tsilou E, Kleiner DE, Huizing M, Turkbey B, 
Choyke P, Guay-Woodford L, Heller T, Szymanska K, Johnson CA, Glass I, Gahl WA: MKS3-related 
ciliopathy with features of autosomal recessive polycystic kidney disease, nephronophthisis, and 
Joubert Syndrome. The Journal of pediatrics, 155: 386-392 e381, 2009 
3. Joubert M, Eisenring JJ, Robb JP, Andermann F: Familial agenesis of the cerebellar vermis. A syndrome 
of episodic hyperpnea, abnormal eye movements, ataxia, and retardation. Neurology, 19: 813-
825, 1969 
4. Maria BL, Quisling RG, Rosainz LC, Yachnis AT, Gitten J, Dede D, Fennell E: Molar tooth sign in Joubert 
syndrome: clinical, radiologic, and pathologic significance. J Child Neurol, 14: 368-376, 1999 
5. Parisi M, Glass I: Joubert Syndrome and Related Disorders. In: GeneReviews(R).  edited by PAGON, R. 
A., ADAM, M. P., ARDINGER, H. H., BIRD, T. D., DOLAN, C. R., FONG, C. T., SMITH, R. J. H., 
STEPHENS, K., Seattle (WA), 1993,  
6. Romani M, Micalizzi A, Valente EM: Joubert syndrome: congenital cerebellar ataxia with the molar 
tooth. Lancet neurology, 12: 894-905, 2013 
7. Satran D, Pierpont ME, Dobyns WB: Cerebello-oculo-renal syndromes including Arima, Senior-Loken 
and COACH syndromes: more than just variants of Joubert syndrome. Am J Med Genet, 86: 459-
469, 1999 
8. Gleeson JG, Keeler LC, Parisi MA, Marsh SE, Chance PF, Glass IA, Graham Jr JM, Maria BL, Barkovich AJ, 
Dobyns WB: Molar tooth sign of the midbrain-hindbrain junction: occurrence in multiple distinct 
syndromes. Am J Med Genet A, 125A: 125-134; discussion 117, 2004 
9. Saraiva JM, Baraitser M: Joubert syndrome: a review. Am J Med Genet, 43: 726-731, 1992 
10. Bachmann-Gagescu R, Dempsey JC, Phelps IG, O'Roak BJ, Knutzen DM, Rue TC, Ishak GE, Isabella CR, 
Gorden N, Adkins J, Boyle EA, de Lacy N, O'Day D, Alswaid A, Ramadevi AR, Lingappa L, Lourenco 
C, Martorell L, Garcia-Cazorla A, Ozyurek H, Haliloglu G, Tuysuz B, Topcu M, University of 
Washington Center for Mendelian G, Chance P, Parisi MA, Glass IA, Shendure J, Doherty D: 
Joubert syndrome: a model for untangling recessive disorders with extreme genetic 
heterogeneity. J Med Genet, 52: 514-522, 2015 
11. Hildebrandt F, Nothwang HG, Vossmerbaumer U, Springer C, Strahm B, Hoppe B, Keuth B, 
Fuchshuber A, Querfeld U, Neuhaus TJ, Brandis M: Lack of large, homozygous deletions of the 
nephronophthisis 1 region in Joubert syndrome type B. APN Study Group. Arbeitsgemeinschaft 
fur Padiatrische Nephrologie. Pediatr Nephrol, 12: 16-19, 1998 
12. Steinlin M, Schmid M, Landau K, Boltshauser E: Follow-up in children with Joubert syndrome. 
Neuropediatrics, 28: 204-211, 1997 
13. Boycott KM, Parboosingh JS, Scott JN, McLeod DR, Greenberg CR, Fujiwara TM, Mah JK, Midgley J, 
Wade A, Bernier FP, Chodirker BN, Bunge M, Innes AM: Meckel syndrome in the Hutterite 
population is actually a Joubert-related cerebello-oculo-renal syndrome. American journal of 
medical genetics Part A, 143A: 1715-1725, 2007 
18 
 
14. Warady BA, Cibis G, Alon U, Blowey D, Hellerstein S: Senior-Loken syndrome: revisited. Pediatrics, 
94: 111-112, 1994 
15. Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, 
Fausett BV, Utsch B, Khanna H, Liu Y, Drummond I, Kawakami I, Kusakabe T, Tsuda M, Ma L, Lee 
H, Larson RG, Allen SJ, Wilkinson CJ, Nigg EA, Shou C, Lillo C, Williams DS, Hoppe B, Kemper MJ, 
Neuhaus T, Parisi MA, Glass IA, Petry M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, 
Nurnberg P, Swaroop A, Leroux MR, Hildebrandt F: The centrosomal protein nephrocystin-6 is 
mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet, 38: 674-681, 
2006 
16. Utsch B, Sayer JA, Attanasio M, Pereira RR, Eccles M, Hennies HC, Otto EA, Hildebrandt F: 
Identification of the first AHI1 gene mutations in nephronophthisis-associated Joubert 
syndrome. Pediatr Nephrol, 21: 32-35, 2006 
17. Poretti A, Snow J, Summers AC, Tekes A, Huisman TA, Aygun N, Carson KA, Doherty D, Parisi MA, 
Toro C, Yildirimli D, Vemulapalli M, Mullikin JC, Program NCS, Cullinane AR, Vilboux T, Gahl WA, 
Gunay-Aygun M: Joubert syndrome: neuroimaging findings in 110 patients in correlation with 
cognitive function and genetic cause. Journal of medical genetics, 2017 
18. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, Furth SL, 
Munoz A: Improved equations estimating GFR in children with chronic kidney disease using an 
immunonephelometric determination of cystatin C. Kidney Int, 82: 445-453, 2012 
19. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van 
Lente F, Greene T, Coresh J, Ckd EPI: A new equation to estimate glomerular filtration rate. Ann 
Intern Med, 150: 604-612, 2009 
20. Vilboux T, Doherty DA, Glass IA, Parisi MA, Phelps IG, Cullinane AR, Zein W, Brooks BP, Heller T, 
Soldatos A, Oden NL, Yildirimli D, Vemulapalli M, Mullikin JC, Nisc Comparative Sequencing P, 
Malicdan MC, Gahl WA, Gunay-Aygun M: Molecular genetic findings and clinical correlations in 
100 patients with Joubert syndrome and related disorders prospectively evaluated at a single 
center. Genetics in medicine : official journal of the American College of Medical Genetics, 2017 
21. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, 
Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush 
MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, 
Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, 
Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, 
Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, Aniebo IC, 
Bailey DM, Bancarz IR, Banerjee S, Barbour SG, Baybayan PA, Benoit VA, Benson KF, Bevis C, 
Black PJ, Boodhun A, Brennan JS, Bridgham JA, Brown RC, Brown AA, Buermann DH, Bundu AA, 
Burrows JC, Carter NP, Castillo N, Chiara ECM, Chang S, Neil Cooley R, Crake NR, Dada OO, 
Diakoumakos KD, Dominguez-Fernandez B, Earnshaw DJ, Egbujor UC, Elmore DW, Etchin SS, 
Ewan MR, Fedurco M, Fraser LJ, Fuentes Fajardo KV, Scott Furey W, George D, Gietzen KJ, 
Goddard CP, Golda GS, Granieri PA, Green DE, Gustafson DL, Hansen NF, Harnish K, 
Haudenschild CD, Heyer NI, Hims MM, Ho JT, Horgan AM, Hoschler K, Hurwitz S, Ivanov DV, 
Johnson MQ, James T, Huw Jones TA, Kang GD, Kerelska TH, Kersey AD, Khrebtukova I, Kindwall 
AP, Kingsbury Z, Kokko-Gonzales PI, Kumar A, Laurent MA, Lawley CT, Lee SE, Lee X, Liao AK, 
Loch JA, Lok M, Luo S, Mammen RM, Martin JW, McCauley PG, McNitt P, Mehta P, Moon KW, 
Mullens JW, Newington T, Ning Z, Ling Ng B, Novo SM, O'Neill MJ, Osborne MA, Osnowski A, 
Ostadan O, Paraschos LL, Pickering L, Pike AC, Chris Pinkard D, Pliskin DP, Podhasky J, Quijano VJ, 
Raczy C, Rae VH, Rawlings SR, Chiva Rodriguez A, Roe PM, Rogers J, Rogert Bacigalupo MC, 
Romanov N, Romieu A, Roth RK, Rourke NJ, Ruediger ST, Rusman E, Sanches-Kuiper RM, 
Schenker MR, Seoane JM, Shaw RJ, Shiver MK, Short SW, Sizto NL, Sluis JP, Smith MA, Ernest 
19 
 
Sohna Sohna J, Spence EJ, Stevens K, Sutton N, Szajkowski L, Tregidgo CL, Turcatti G, 
Vandevondele S, Verhovsky Y, Virk SM, Wakelin S, Walcott GC, Wang J, Worsley GJ, Yan J, Yau L, 
Zuerlein M, Mullikin JC, Hurles ME, McCooke NJ, West JS, Oaks FL, Lundberg PL, Klenerman D, 
Durbin R, Smith AJ: Accurate whole human genome sequencing using reversible terminator 
chemistry. Nature, 456: 53-59, 2008 
22. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL: New equations to 
estimate GFR in children with CKD. J Am Soc Nephrol, 20: 629-637, 2009 
23. Braun DA, Hildebrandt F: Ciliopathies. Cold Spring Harb Perspect Biol, 9, 2017 
24. Stokman M, Lilien M, Knoers N: Nephronophthisis. In: GeneReviews(R).  edited by PAGON, R. A., 
ADAM, M. P., ARDINGER, H. H., WALLACE, S. E., AMEMIYA, A., BEAN, L. J. H., BIRD, T. D., 
LEDBETTER, N., MEFFORD, H. C., SMITH, R. J. H., STEPHENS, K., Seattle (WA), 1993,  
25. Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman M, Graf J, Bryant JC, Kleta R, Garcia A, 
Edwards H, Piwnica-Worms K, Adams D, Bernardini I, Fischer RE, Krasnewich D, Oden N, Ling A, 
Quezado Z, Zak C, Daryanani KT, Turkbey B, Choyke P, Guay-Woodford LM, Gahl WA: Correlation 
of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with 
autosomal recessive polycystic kidney disease. Clinical journal of the American Society of 
Nephrology : CJASN, 5: 972-984, 2010 
26. Malaki M, Nemati M, Shoaran M: Joubert syndrome presenting as unilateral dysplastic kidney, 
hypotonia, and respiratory problem. Saudi journal of kidney diseases and transplantation : an 
official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 23: 325-329, 
2012 
27. Schreuder MF, Westland R, van Wijk JA: Unilateral multicystic dysplastic kidney: a meta-analysis of 
observational studies on the incidence, associated urinary tract malformations and the 
contralateral kidney. Nephrol Dial Transplant, 24: 1810-1818, 2009 
28. Parisi MA, Doherty D, Eckert ML, Shaw DW, Ozyurek H, Aysun S, Giray O, Al Swaid A, Al Shahwan S, 
Dohayan N, Bakhsh E, Indridason OS, Dobyns WB, Bennett CL, Chance PF, Glass IA: AHI1 
mutations cause both retinal dystrophy and renal cystic disease in Joubert syndrome. Journal of 
medical genetics, 43: 334-339, 2006 
29. Vivante A, Kleppa MJ, Schulz J, Kohl S, Sharma A, Chen J, Shril S, Hwang DY, Weiss AC, Kaminski MM, 
Shukrun R, Kemper MJ, Lehnhardt A, Beetz R, Sanna-Cherchi S, Verbitsky M, Gharavi AG, Stuart 
HM, Feather SA, Goodship JA, Goodship TH, Woolf AS, Westra SJ, Doody DP, Bauer SB, Lee RS, 
Adam RM, Lu W, Reutter HM, Kehinde EO, Mancini EJ, Lifton RP, Tasic V, Lienkamp SS, Juppner 
H, Kispert A, Hildebrandt F: Mutations in TBX18 Cause Dominant Urinary Tract Malformations 
via Transcriptional Dysregulation of Ureter Development. Am J Hum Genet, 97: 291-301, 2015 
30. Nakayama M, Nozu K, Goto Y, Kamei K, Ito S, Sato H, Emi M, Nakanishi K, Tsuchiya S, Iijima K: HNF1B 
alterations associated with congenital anomalies of the kidney and urinary tract. Pediatr 
Nephrol, 25: 1073-1079, 2010 
31. Hasui M, Kaneko K, Tsuji S, Isozaki Y, Kimata T, Nozu Y, Nozu K, Iijima K: Different phenotypes of 
HNF1ss deletion mutants in familial multicystic dysplastic kidneys. Clin Nephrol, 79: 484-487, 
2013 
32. Zaki MS, Sattar S, Massoudi RA, Gleeson JG: Co-occurrence of distinct ciliopathy diseases in single 
families suggests genetic modifiers. Am J Med Genet A, 155A: 3042-3049, 2011 
33. Maglic D, Stephen J, Malicdan MC, Guo J, Fischer R, Konzman D, Program NCS, Mullikin JC, Gahl WA, 
Vilboux T, Gunay-Aygun M: TMEM231 Gene Conversion Associated with Joubert and Meckel-
Gruber Syndromes in the Same Family. Human mutation, 37: 1144-1148, 2016 
34. Forsythe E, Sparks K, Best S, Borrows S, Hoskins B, Sabir A, Barrett T, Williams D, Mohammed S, 
Goldsmith D, Milford DV, Bockenhauer D, Foggensteiner L, Beales PL: Risk Factors for Severe 
Renal Disease in Bardet-Biedl Syndrome. J Am Soc Nephrol, 28: 963-970, 2017 
20 
 
35. al-Khaldi N, Watson AR, Zuccollo J, Twining P, Rose DH: Outcome of antenatally detected cystic 
dysplastic kidney disease. Arch Dis Child, 70: 520-522, 1994 
36. Eickmeyer AB, Casanova NF, He C, Smith EA, Wan J, Bloom DA, Dillman JR: The natural history of the 
multicystic dysplastic kidney--is limited follow-up warranted? J Pediatr Urol, 10: 655-661, 2014 
 
A 
A 
C 
B 
D 
* 
* 
Figure 1 
Figure 2 A B 
C 
D 
L R L R 
P
a
ti
en
t 
N
o
F
a
m
il
y
 N
o
N
IH
 C
il
io
p
a
th
y
t 
N
o
G
en
d
er
A
g
e 
(y
)
G
en
e
Mutation 1 Mutation 2
P
o
ly
d
a
ct
y
ly
C
o
lo
b
o
m
a
R
et
in
a
l 
D
y
st
ro
p
h
y
L
iv
er
 D
is
ea
se
 
K
id
n
ey
 D
is
ea
se
K
id
n
ey
 U
S
G
F
R
 
(m
l/
m
in
/1
.7
3
m
2
) 
1 1 361 m 0.9 TMEM67 c.1538A>G; p.(Tyr513Cys) c.2122G>A; p.(Ala708Thr) - + - + - N 145
2 2 545 f 2.2 TMEM67 c.622A>T; p.(Arg208*) c.2140_2142del; p.(Ser715del) - - - + - N 117
3 3 97 m 3.9 TMEM67 c.755T>C; p.(Met252Thr) c.1843T>C; p.(Cys615Arg) - + - - + Ab 28
£ (12) 
4 4 548 m 4.5 TMEM67 c.748G>A, p.(Gly250Arg) c.2879C>T; p.(Ala960Val) - + - + + Ab 146
5 5** 216 f 4.9 TMEM67 c.2522A>C; p.(Gln841Pro) c.622A>T; p.(Arg208*) - + - + + Ab 69
£(12)
6 302 m 5.1 TMEM67 c.2802delA; p.(Asn935Metfs*25) Not identified - + - + - N 108
7 301 m 9.5 TMEM67 c.2802delA; p.(Asn935Metfs*25) Not identified - + - + - N 113
8 271 f 6.7 TMEM67 c.1843 T>C; p.(Cys615Arg) c.1843 T>C; p.(Cys615Arg) - - - + + Ab 27
£(8)
9 272 m 9.3 TMEM67 c.1843 T>C; p.(Cys615Arg) c.1843 T>C; p.(Cys615Arg) - - - + + Tx Tx (7)
10 557 m 6.8 TMEM67 c.579_580del; p.(Gly195Ilefs*13) c.950C>G; p.(Thr317Arg) - + - + + Ab 129
11 559 m 16.7 TMEM67 c.579_580del; p.(Gly195Ilefs*13) c.950C>G; p.(Thr317Arg) - + - + + Ab 59
12 9 459 f 7.8 TMEM67 c.1081G>T; p.(Glu361*) c.2661+5G>A - + - + - N 104
13 10 238 m 8.2 TMEM67 c.224-2 A>T c.1843 T>C; p.(Cys615Arg) - - - + + Ab 38
£(10)
14 11 255 m 9 TMEM67 c.297G>T; p.(Lys99Asn) c.2322+2dup - + - + - N 118
15 12 542 f 11.9 TMEM67 c.1538 A>G; p.(Thr513Cys) c. 2498 T>C; p.(Ile833Thr) - + - + - N 134
16 13 303 f 14.7 TMEM67 c. 2498 T>C; p.(Ile833Thr) c.1351C>T; p.(Arg451*) - + - + + Tx Tx (13)
17 14** 252 f 14.8 TMEM67 c.1674+3A>G c.1126C>G; p.(Gln376Glu) - + - + + Ab 83
18 15 309 m 17.4 TMEM67 c.769A>G; p.(Met257Val) Not identified - + - + + Ab 106
19 562 m 22.9 TMEM67 c.755T>C; p.(Met252Thr) c.245C>G; p.(Pro82Arg) - + - + - N 103
20 561 m 24.9 TMEM67 c.755T>C; p.(Met252Thr) c.245C>G; p.(Pro82Arg) - + - + - N 92
21 560 m 29.6 TMEM67 c.755T>C; p.(Met252Thr) c.245C>G; p.(Pro82Arg) - + - + - N 89
22 17 432 f 36.2 TMEM67 c.2322+2dup c.2661+5G>A - + + + - N 99
23 488 m 0.6 C5orf42 c.7988_7989del; p.(Gly2663Alafs*40) c.7988_7989del; p.(Gly2663Alafs*40) - - - - - N 79
24 487 f 5.3 C5orf42 c.7988_7989del; p.(Gly2663Alafs*40) c.7988_7989del; p.(Gly2663Alafs*40) - - - - - N 94
25 19 355 f 2.1 C5orf42 c.1784T>G; p.(Leu595*) c.5348C>A; p.(Ala1783Asp) - - - - - N 99
95 20 458 f 2.2 C5orf42 c.1819del; p.(Tyr607Thrfs*6) Not identified - - - - - N 126
26 21 523 f 2.3 C5orf42 c.510dup; p.(Leu171Serfs*8) c.8710C>T; p.(Arg2904*) - - - + - N 125
27 22 471 m 8 C5orf42 c.1819del; p.(Tyr607Thrfs*6) c.7817T>A; p.(Leu2606*) + - - - - N 135
28 23 534 f 8.4 C5orf42 c.2999G>T; p.(Trp1000Leu) c.3001A>G; p.(Thr1001Ala) and c.8855+1G>A - + - - - N 102
29 501 m 10 C5orf42 c.7190del; p.(Pro2397Glnfs*37) c.8710C>T; p.(Arg2904*) + - - + - N 119
30 500 f 11.8 C5orf42 c.7190del; p.(Pro2397Glnfs*37) c.8710C>T; p.(Arg2904*) + - - + - N 196
Table 1. Summary of Molecular Genetic and Main Clinical Findings of 100 Joubert Sydrome Patients Evaluated at the NIH Clinical Center.
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7
8
16
18
24
31 25 404 m 10.3 C5orf42 c.2923C>T; p.(Gln975*) c.8710C>T; p.(Arg2904*) - - - - - N 86
32 26 568 f 14.1 C5orf42 c.5737+2T>C c.2624C>T; p.(Ser875Phe) - - - - - N 120
33 27 528 m 18.8 C5orf42 c.455C>T; p.(Ser152Phe) c.2334G>A; p.(Trp778*) - - - + - N 109
34 28 491 m 19 C5orf42 c.7477C>T; p.(Arg2493*) c.8263dup; p.(Thr2755Asnfs*8) - - - - - N 106
35 482 f 24.5 C5orf42 c.1784T>G; p.(Leu595*) c.8263_8264insG; p.(Thr2755Serfs*8) + - - + - N 83
36 481 m 27.6 C5orf42 c.1784T>G; p.(Leu595*) c.8263_8264insG; p.(Thr2755Serfs*8) + - - + - N 104
37 30 378 f 1.8 CC2D2A c.3975+4_3975+7del c.4667A>T; p.(Asp1556Val) - - - + - N 144
38 31 483 f 2.3 CC2D2A c.248-4_248-3insAAGTTTT c.3452T>C; p.(Val1151Ala) - - - - - N 68
39 32 575 f 2.3 CC2D2A c.3289del; p.(Val1097Phefs*2) c.4667A>T; p.(Asp1556Val) - - - - + Ab 119
40 33 495 m 3.5 CC2D2A c.4741A>G; p.(Thr1581Ala) c.3347C>T; p.(Thr1116Met) - - - - - N 118
41 34** 446 m 3.2 CC2D2A c.3289del; p.(Val1097Phefs*2) c.3851G>A; p.(Arg1284His) + + - - - N 103
42 35 185 m 3.6 CC2D2A c.3145C>T; p.(Arg1049*) c.3347C>T; p.(Thr1116Met) - - - + + Ab 66
43 577 f 13.1 CC2D2A c.3743_3746dup; p.(Pro1250Glyfs*11) c.3989G>A; p.(Arg1330Gln) - - - - - N 115
44 576 f 15.7 CC2D2A c.3743_3746dup; p.(Pro1250Glyfs*11) c.3989G>A; p.(Arg1330Gln) - - - - - N 109
45 37 565 f 15.4 CC2D2A c.1017+1G>A c.4600T>G; p.(Leu1534Val) - - + + - N 127
46 38 364 f 16.3 CC2D2A c.3055C>T; p.(Arg1019*) c.3288G>C; p.(Gln1096His) - - - - - N 99
47 39 480 m 0.9 CEP290 c.5182G>T; p.(Glu1728*) c.5668G>T; p.(Gly1890*) - - - - + Ab 90
48 40 552 m 4.3 CEP290 c.4723A>T; p.(Lys1575*) c.4966G>T; p.(Glu1656*) - - + - + Ab 115
49 41 373 m 4.4 CEP290 c.4882C>T; p.(Gln1628*) c.6072C>A; p.(Tyr2024*) - - + + + Ab 55
£(6)
50 42 455 m 6.9 CEP290 c.1623+1G>A c.5668G>T; p.(Gly1890*) - - + - - N 76
51 43 412 m 10 CEP290 c.1666dup; p.(Ile556Asnfs*20) c.5344C>T; p.(Arg1782*) - - + - + Ab 35
52 44** 213 f 13.2 CEP290 c.5611_5614del; p.(Gln1871Valfs*2) c.4882C>T; p.(Gln1628*) - + + - + Tx Tx (9)
53 45 441 f 23.5 CEP290 c.5668G>T; p.(Gly1890*) c.5356_5571del; p.(Glu1786_Leu1857del) - + + - + Ab 21
£(24)
54 46 513 m 1.9 AHI1 c.1997A>T; p.(Asp666Val) c.2297G>A; p.(Gly766Glu) - - - - - N 103
55 47 517 m 3.3 AHI1 c.662C>A; p.(Ser221*) c.1583C>G; p.(Ser528*) - - + + + Ab 108
56 48 472 m 5 AHI1 c.1976A>T; p.(Asp659Val) c.2212C>T; p.(Arg738*) - - + - - N 101
57 49 574 m 5.1 AHI1 c.910dup; p.(Thr304Asnfs*6) c.2105C>T; p.(Thr702Met) - - + - - N 114
58 50 540 f 17.9 AHI1 c.1115A>G; p.(Asp372Gly) c.2173T>C; p.(Trp725Arg) - - + + + Ab 92
59 51 228 f 20.9 AHI1 c.736A>T; p.(Lys246*) c.2495T>G; p.(Leu832*) - - + + + Ab 219
60 52 443 f 2.2 KIAA0586 c.392del; p.(Arg131Lysfs*4) c.1254-1G>C - - - - - N 81
61 53 368 m 4 KIAA0586 c.392del; p.(Arg131Lysfs*4) c.1000C>T; p.(Gln334*) - + - - - N 114
62 54 494 m 4.4 KIAA0586 c.94dup; p.(His32Profs*8) c.586-350_1129+1117del - + - - - N 88
63 55 579 m 4.4 KIAA0586 c.392del; p.(Arg131Lysfs*4) c.586-350_1129+1117del - - - - - N 122
64 56 507 m 4.7 KIAA0586 c.831C>T; p.(Leu277Leu) c.586-350_1129+1117del - - - - - N 102
65 57 531 m 13.6 KIAA0586 c.392del; p.(Arg131Lysfs*4) c.961+1G>A - - - - - N 126
66 58 502 m 1.5 MKS1 c.1389G>T; p.(Arg463Arg) c.493C>T; p.(Arg165Cys) - - - - - N 91
67 59 397 m 1.7 MKS1 c.950G>A; p.(Gly317Glu) c.1115_1117del; p.(Ser372del) + - + - - N 137
68 60 537 m 2 MKS1 c.417G>A; p.(Glu139Glu) c.1476T>G; p.(Cys492Trp) + - + + - N 115
69 61 510 m 8 MKS1 c.1408-36_1408-6del c.1387C>G; p.(Arg463Gly) - - + - - N 111
70 62 573 m 14 MKS1 c.417G>A; p.(Glu139Glu) c.1208C>T; p.(Ser403Leu) - - + - - N 134
29
36
71 63 372 m 3.2 INPP5E c.473delG; p.(Gly158Valfs*40) c.1304G>A; p.(Arg435Gln) - + + - + Ab 137
72 64 352 m 14.5 INPP5E c.1784_1787del; p.(Val595Glyfs*21) c.1862G>A; p.(Arg621Gln) - - + + + Tx Tx(6)
73 7504 f 19 INPP5E c.1565G>C; p.(Gly522Ala) c.1565G>C; p.(Gly522Ala) - - + - - N 105
74 7503 f 21 INPP5E c.1565G>C; p.(Gly522Ala) c.1565G>C; p.(Gly522Ala) - - + - - N 156
75 520 f 1.2 TMEM231 c.712G>A; p.(Asp238Asn) g.18555_19148conNG_026383.1:g.2718_3301; p.(Ile224Leufs*5) - - - + - N 93
76 518 f 4.8 TMEM231 c.712G>A; p.(Asp238Asn) g.18555_19148conNG_026383.1:g.2718_3301; p.(Ile224Leufs*5) - - + - - N 110
77 519 f 4.8 TMEM231 c.712G>A; p.(Asp238Asn) g.18555_19148conNG_026383.1:g.2718_3301; p.(Ile224Leufs*5) - - + - - N 110
78 67 438 m 3.4 NPHP1 290 kb common deletion 290 kb common deletion - - - - + Ab 117
79 463 f 15.9 NPHP1 290 kb common deletion 290 kb common deletion - - + - + Tx Tx(11)
80 462 m 18.1 NPHP1 290 kb common deletion 290 kb common deletion - - + - + Tx Tx (13)
81 69 396 f 9 TMEM216 c.218G>T; p.(Arg73Leu) c.253C>T; p.(Arg85*) + - - + + N 52
82 70 408 m 12 TMEM216 c.218G>T; p.(Arg73Leu) c.218G>T; p.(Arg73Leu) + + - - - N 86
83 71 3331 m 4.3 OFD1 c.2656del; p.(Gln886Lysfs*2) Not applicable as X-linked - - + - - N 133
84 72 452 m 12.3 OFD1 c.149A>G; p.(His50Arg) Not applicable as X linked - - - + - N 158
85 73 466 f 2.3 CSPP1 c.2244_2245del; p.(Glu750Glyfs*30) c.2280del; p.(Glu761Lysfs*35) - - + - - N 117
86 74 387 f 3.5 CSPP1 c.1835_1845del; p.Arg612Thrfs*2 c.2814-1G>C - - - - - N 88
87 75 409 m 2.1 KIF7 c.3505C>T; p.(Gln1169*) c.3505C>T; p.(Gln1169*) - - - - - N 97
88 76 400 m 4.8 B9D1 c.95A>G; p.(Tyr32Cys) c.466C>T; p.(Arg156Trp) - - - - - N 113
89 77 290 f 8 CEP164 c.195-2A>T c.277C>T; p.(Arg93Trp) + - + + + Tx Tx(7)
90 78 360 m 21.4 RPGRIP1L c.671_677del; p.(Glu224Glyfs*7) c.1340T>C; p.(Leu447Ser) and c.3790G>T; p.(Asp1264Tyr) + + - - + Ab 33
97 79 474 f 4.5 TMEM237 c.76C>T; p.(Gln26*) c.943+1G>T - + + - + Ab 52
92 390 f 1.9 KIAA0753 c.769A>G; p.(Arg257Gly) c.2359-1G>C - - - - - N 85
93 389 m 7 KIAA0753 c.769A>G; p.(Arg257Gly) c.2359-1G>C - - - - - N 84
99 81 449 f 7.9 CELSR2 c.1150G>A; p.(Ala384Thr) c.6908C>T; p.(Thr2303Met) - - - + - N 95
91 82 393 m 1.7 Unknown Not identified Not identified + + - + - N 116
96 83 578 f 2.3 Unknown Not identified Not identified - + - - - N 104
98 84 570 m 4.7 Unknown Not identified Not identified - - - - - N 118
94 85 419 f 2 Unknown Not identified Not identified - - + - - N 106
100 86 358 m 9.1 Unknown Not identified Not identified - - - + + Ab 34
£(15)
Patients are grouped by gene and within each gene patients are sorted from the youngest to oldest. US: ultrasonography;  GFR: glomerular filtration rate; CMD:corticomedullary differentiation; 
Tx( ):Transplanted(age at transplantation in years); *Kidney ultrasonography findings are bilateral unless otherwise specified  
¥
Hypertension diagnosed before decrease in GFR.  
£ ( )
These 
patients received renal transplantation after the NIH visit, ages at transplanation in years are indicated in parenthesis. **These 4 families had history of another affected sibling. 
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Kidney Histopathology
Specific Type of 
Fibrocystic Kidney 
disease 
3 3 97
m 3.9 TMEM67
Prenatal US normal. 
Oligohydramnios at delivery, 
kidneys palpable at birth
Diffuse moderate hyperechogenicity, loss of 
CMD, small cysts  in cortex and medulla - 3.6, - 4.3 28
£ (12) 
+
NP ARPKD-NPHP
4 4 548 m 4.5 TMEM67 N Loss of CMD - 0.1, +1.5 146 - NP NPHP
5 5 216
f 4.9 TMEM67
18 week, oligohydramnios, 
enlarged diffusely hyperechoic 
cystic kidneys (affected sibling's 
prenatal US showed hydrocephalus, 
large cystic kidneys, 
oligohydramnios)
Several cysts in left kidney, normal echogenicity 
and  CMD - 0.2, at mean 69
£(12)
+
NP ARPKD-NPHP
8 271
f 6.7 TMEM67
20 week, enlarged diffusely 
hyperechoic kidneys with scattered 
cysts, no oligohydramnios 
Diffuse moderate hyperechogenicity, loss of 
CMD, cysts in cortex and medulla +0.6,  -0.2 27
£(8)
+
Extracted R kidney: histopathological findings consistent with 
autosomal recessive polycystic kidney disease and interstitial 
nephritis and glomerulosclerosis ARPKD-NPHP
9 272
m 9.3 TMEM67 N Tx Tx Tx (7)
+
Extracted R kidney: Moderate chronic interstitial nephritis, 
glomerulosclerosis, tubular atrophy, and nephrocalcinosis as well as 
cysts, mostly accumulated at the CM junction but also scattered 
throughout the cortex and medulla ARPKD-NPHP
10 557 m 6.8 TMEM67 N Diffuse mild hyperechogenicity, loss of CMD - 2.5,  -1.9 129 - NP NPHP 
11 559
m 16.7 TMEM67 N
Diffuse moderate hyperechogenicity, loss of 
CMD, medullary cysts -0.5,  -1.3 59
+
NP ARPKD-NPHP
13 10 238
m 8.2 TMEM67
19 week, enlarged diffusely 
hyperechoic kidneys with loss of 
CMD, progressive oligohydramnios 
Diffuse moderate hyperechogenicity, loss of 
CMD, cysts in cortex and medulla +2.6, +2.3 38
£(10)
+
NA ARPKD-NPHP
16 13 303
f 14.7 TMEM67 N Tx Tx Tx (13)
+
Extracted R kidney: (51 gr, 8.5 X 4.4 X 2.8 cm), Extensive 
glomerulosclerosis, tubular atrophy, and interstitial fibrosis with 
severe chronic inflammation without any evidence of dysplasia. A 
few thin walled tubular cysts at CM junction ARPKD-NPHP
17 14 252
f 14.8 TMEM67
N (affected sibling's prenatal US 
showed polycystic kidneys, 
hydrocephalus)
Multiple cysts in cortex and medulla of right 
kidney, normal echogenicity and  CMD - 1.8, - 0.9 83
-
NP
Cystic, unable to 
classify
18 15 309
m 17.4 TMEM67 N
Multiple cysts in cortex and medulla, normal 
echogenicity and  CMD - 0.2, +1.3 106
-
NP
Cystic, unable to 
classify
47 39 480
m 0.9 CEP290 N
Multiple cysts in cortex and medulla of right 
kidney, normal echogenicity and CMD - 1.7, -2.8 90
-
NP
Cystic, unable to 
classify
48 40 552
m 4.3 CEP290 N
Multiple cysts in cortex and medulla of both 
kidneys, normal echogenicity and  CMD -0.7, -1.4 115
-
NP
Cystic, unable to 
classify
49 41 373
m 4.4 CEP290
20 week, left multicystic dysplastic 
kidney; right kidney normal
Atrophic multicystic left kidney without any 
normal parenchyma (5.5cm), several cortical 
cysts in right kidney (8.8 cm) 
+1.9, atrophic 
MCDK 55
£(6)
-
NP Unilateral MCDK
51 43 412 m 10 CEP290 N Multiple medullary cysts, normal echogenicity - 0.9, -0.9 35 - NP NPHP
52 44 213
f 13.2 CEP290
19 week, hyperechogenic kidneys, 
(resolved in 3rd trimester) Tx Tx Tx (9)
-
NA NPHP
53 45 441 f 23.5 CEP290 N Multiple medullary cysts, moderate hyperechogenicity+0.3, -0.9 21
£(24) - NP NPHP
55 47 517
m 3.3 AHI1
19 week, left multicystic dysplastic 
kidney; right kidney normal
Left kidney could not be visualized, right kidney 
normal (8.4 cm). 
+1.7, atrophic 
MCDK 108
-
NP Unilateral MCDK
58 50 540
f 17.9 AHI1 N
Left kidney with several large cysts, right kidney 
normal size with multiple cysts and moderate 
hyperechogenicity 
+1.9, -0.7 (154 ml, 
and 92 ml)
¥ 
92
-
NP
Cystic, unable to 
classify, 
(asymmetrical)
59 51 228
f 20.9 AHI1 N
Left multicystic dysplastic kidney, Right kidney 
normal (14.9 cm).  
+4.3, atrophic 
MCDK 219
-
NP Unilateral MCDK
78 67 438 m 3.4 NPHP1 N Medullary cysts and echogenic foci in medullary pyramids -1.0, +1.3 117 - NP NPHP
79 463
f 15.9 NPHP1 N Tx Tx Tx(11)
-
Extracted L kidney: (175 gr, 9.5 X 6 X 5.3 cm), marked intestitial 
inflammmation with subcapsular as well as deep cortical 
glomerulosclerosis, interstitial fibrosis and atrophy with medullary 
cysts    NPHP
80 462 m 18.1 NPHP1 N Tx Tx Tx (13) - nephronophthisis/medullary cystic disease NPHP
39 32 575 f 2.3 CC2D2A N Medullary "nephrocalcinosis" -1.8, -0.5 119 - NP NPHP
42 35 185 m 3.6 CC2D2A N Loss of CMD -3.4, -2.0 66 - NP NPHP
71 63 372
m 3.2 INPP5E 8 months, oligohydramnios 
Multiple medullary cysts, loss of CMD, moderate 
hyperechogenicity +3.9, +3.7 137
-
NP ARPKD-NPHP
72 64 352 m 14.5 INPP5E N Tx Tx Tx(6) - NP NPHP
81 69 396
f 9 TMEM216 N N +0.5, -1.64 52
-
NA
Cystic, unable to 
classify, ( bladder 
dysfunction)
89 77 290
f 8 CEP164 N Tx Tx Tx(7)
π -
Biopsy at age 5 years: Chronic sclerosing tubulointerstitial 
nephropathy; there were no cysts NPHP-like
90 78 360 m 21.4 RPGRIP1L N
Diffuse moderate hyperechogenicity, loss of 
CMD, cysts in medulla and cortex +2.0, +1.3 33
- NP
ARPKD-NPHP
97 79 474
f 4.5 TMEM237
20 week, enlarged (3 times normal 
size) kidneys with markedly 
increased echogenicity
Diffuse moderate hyperechogenicity, loss of 
CMD, echogenic foci and cysts in medulla and 
cortex +1.3, - 1.8 52
-
NP ARPKD-NPHP
100 86 358
m 9.1 Unknown N
Moderate hyperechogenicity especially in the 
cortex, single cortical cyst in right kidney -0.5. -0.5 34
£(15) -
NP
Cystic, unable to 
classify
Patients are grouped by gene and within each gene patients are sorted from the youngest to oldest. US: renal ultrasonography;  SD: standard deviation; GFR: glomerular filtration rate; CMD:corticomedullary differentiation; NP: not performed; NPHP: 
nephronophthisis; ARPKD: autosomal recessive polycystic kidney disease; *Kidney ultrasonography findings are bilateral unless otherwise specified  ¥Hypertension diagnosed before any decrease in GFR. Tx( ): Transplanted(age at transplantation in years);  £ ( 
)These patients received renal transplantation after the NIH visit, ages at transplanation in years are indicated in parenthesis. π: This patient (290) reached ESRD at age 5 and was on peritoneal dialysis for 2 years. ¥ MRI based kidney volumes. 
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Table 2. Characteristics of Kidney Disease in 32 Joubert Syndrome patients with Kidney involvement
